Viagra, an oral therapy for erectile dysfunction, is the citrate salt of sildenafil, a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5).
According to the court’s decision, Teva will not be able to receive approval for generic Viagra till October 2019.
Pfizer executive vice president and general counsel Amy Schulman said protecting the intellectual property rights of their core is critical, and the court decision acknowledges Teva’s clear violation of their patent rights.